Merus (MRUS) TD Cowen 45th Annual Healthcare Conference summary

Conference overview

• The session featured a fireside chat with the CEO, focusing on clinical and regulatory progress in oncology, especially multispecific antibody innovation.

• The company leverages monoclonal antibody processes to develop bispecifics, aiming to reduce risk and improve clinical success rates.

• Five molecules have entered the clinic, with three showing strong clinical activity, including an FDA-approved therapy for NRG1 fusion cancers.

• The pipeline is considered robust for a small company, with significant promise projected for 2025 and beyond.

Regulatory and clinical milestones

• Petosemtamab received two FDA breakthrough therapy designations, validating its clinical data in head and neck cancer.

• Breakthrough designation enables regulatory flexibility and more direct engagement with senior FDA staff.

• The FDA’s willingness to grant breakthrough status for a combination therapy is rare and seen as a strong endorsement.

• The company expects a major clinical update for the frontline combination in the first half of the year.

Clinical data and competitive landscape

• Petosemtamab has shown a 67% response rate, with most patients surpassing the median PFS of the control arm.

• Key efficacy endpoints for registration trials are overall response rate and overall survival, with Keytruda as the control arm.

• Competitors include zanzalintinib and ficerafusp, with a key benchmark being a 9.8-month median PFS.

• Overall survival at 12 months is considered the ultimate approval endpoint, with Keytruda’s rate at 50%-59%.